Clinical trials in central nervous system (CNS) disorders are notoriously difficult to design. The complexity of these trials and the low success rates in Phase II and Phase III studies are driven by several factors:

• Slow progression of the disease
• Extended treatment durations
• Heterogeneous patient populations
• Subjective endpoints
• Strong placebo effects

Join this webinar to discover latest statistical innovations in designing CNS trials for drug approval — helping minimize the common risks and improving efficiencies. This session will feature a short review of regulatory guidelines and showcase recent successful trials in Alzheimer’s Disease and other neurological disorders.

Speaker

James Matcham, VP Strategic Consulting